Theriva Biologics (FRA:SFY0) Cyclically Adjusted FCF per Share: €-8,074.49 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SFY0 Theriva Biologics Inc FRA:SFY0
26 GF Score
Price €2.42
! 3 Warning Signs
View Full Analysis

What is Theriva Biologics Cyclically Adjusted FCF per Share?

Theriva Biologics FRA:SFY0 26 Cyclically Adjusted FCF per Share is €-8,074.49 as of Mar. 2026. GuruFocus rates FRA:SFY0 with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Theriva Biologics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.052. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-8,074.49 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 24.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 14.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Theriva Biologics was 29.00% per year. The lowest was -1.50% per year. And the median was 9.15% per year.

As of today (2026-07-23), Theriva Biologics's current stock price is €2.42. Theriva Biologics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-8,074.49. Theriva Biologics's Cyclically Adjusted Price-to-FCF of today is .


Theriva Biologics  (FRA:SFY0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Theriva Biologics Cyclically Adjusted FCF per Share Related Terms


Theriva Biologics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Theriva Biologics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theriva Biologics Cyclically Adjusted FCF per Share Chart

Theriva Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,465.18 -1,487.06 -1,339.49 -1,750.60 -8,268.95

Theriva Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,618.46 -6,010.06 -5,208.05 -8,268.95 -8,074.49

FRA:SFY0 vs OSRH, PBM, PHIO: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Theriva Biologics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Cyclically Adjusted Price-to-FCF falls into.


FRA:SFY0
26GF Score
Theriva Biologics Inc FRA:SFY0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theriva Biologics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theriva Biologics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.052/330.2130*330.2130
=-0.052

Current CPI (Mar. 2026) = 330.2130.

Theriva Biologics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -474.182 241.018 -649.665
201609 -546.800 241.428 -747.885
201612 -784.231 241.432 -1,072.614
201703 -432.846 243.801 -586.262
201706 -364.929 244.955 -491.945
201709 -264.133 246.819 -353.377
201712 -221.733 246.524 -297.006
201803 -328.667 249.554 -434.896
201806 -245.867 251.989 -322.191
201809 -192.938 252.439 -252.380
201812 -46.645 251.233 -61.309
201903 -59.333 254.202 -77.075
201906 -39.985 256.143 -51.548
201909 -41.493 256.759 -53.363
201912 -48.433 256.974 -62.237
202003 -66.015 258.115 -84.455
202006 -24.311 257.797 -31.140
202009 -22.308 260.280 -28.302
202012 -30.294 260.474 -38.405
202103 -7.736 264.877 -9.644
202106 -4.081 271.696 -4.960
202109 -3.472 274.310 -4.180
202112 -8.047 278.802 -9.531
202203 -8.049 287.504 -9.245
202206 -6.500 296.311 -7.244
202209 -7.099 296.808 -7.898
202212 -8.030 296.797 -8.934
202303 -8.673 301.836 -9.488
202306 -5.931 305.109 -6.419
202309 -4.235 307.789 -4.544
202312 -8.857 306.746 -9.535
202403 -6.547 312.332 -6.922
202406 -4.133 314.175 -4.344
202409 -3.109 315.301 -3.256
202412 -1.610 315.605 -1.685
202503 -1.581 319.799 -1.632
202506 -0.605 322.561 -0.619
202509 -0.380 324.800 -0.386
202512 -0.069 324.054 -0.070
202603 -0.052 330.213 -0.052

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-8,074.49 mean?
Theriva Biologics (FRA:SFY0) has a Cyclically Adjusted FCF per Share of €-8,074.49 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Theriva Biologics and its competitors.
Is Theriva Biologics' Cyclically Adjusted FCF per Share too high?
Theriva Biologics' current Cyclically Adjusted FCF per Share is €-8,074.49. Overall, Theriva Biologics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' Cyclically Adjusted FCF per Share compare to OSRH and PBM?
Theriva Biologics' Cyclically Adjusted FCF per Share of €-8,074.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Theriva Biologics and its competitors. Theriva Biologics's current Cyclically Adjusted FCF per Share is €-8,074.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (FRA:SFY0) has a current Cyclically Adjusted FCF per Share of €-8,074.49. The current Cyclically Adjusted FCF per Share is €-8,074.49. Theriva Biologics' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Theriva Biologics (FRA:SFY0), the current Cyclically Adjusted FCF per Share is €-8,074.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Theriva Biologics Business Description

Other Exchanges TOVX:USA
Address 9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
26GF Score

Get the complete analysis for FRA:SFY0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.42
Price